Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > One final thought.

<< Previous

Bullboard Posts

Next >>

Comment by baggerx99on Jun 14, 2021 6:56pm

201 Views

Post# 33385969

RE:RE:One final thought.

does anyone have Dan's email?

sidtheritz wrote:
Hello to this community. Been a long time lurker, and I enjoy the engaging posts so thanks to all who share their analysis and insights here. Has been very helpful.

I'm not an expert in investing, but I have had a long run working at startups so wanted to add my two cents here - Dan's focus should be on value creation. That will inevitably increase SP price; in fact, imo that is the best way Dan can represent shareholders.

If Dan didn't sell, what would the SP be? Would there have been an upward momentum? I don't think so.

The question really should be - what is he and mgmt team doing to increase value. And I think you already have the answers to that from other posters.